प्राथमिक स्रोत रिकॉर्ड
निर्णायकटॉपलाइन परिणाम
Iovance ने NSCLC में lifileucel के लिए 26% ORR रिपोर्ट किया, mDOR अभी तक प्राप्त नहीं हुआ
The IOV-LUN-202 trial interim data show a 26% objective response rate and median duration of response not reached after >25 months follow-up in previously treated advanced nonsquamous NSCLC. FDA has already provided positive feedback on the trial design and potency assay matrix; the company expects trial completion in 2026 to support a supplemental BLA with potential launch in 2027.
मुख्य तथ्य
- फाइल किया गया
- 6 नव॰ 2025, 01:05 pm
- घटना
- टॉपलाइन परिणाम
- दिशा
- सकारात्मक
- कंपनी
IOVAIovance- संपत्ति
- lifileucel
- स्रोत
- SEC 8-K
- विश्वसनीयता
- स्रोत सहित
- DCR
- 100%
- cORR
- 40%
- माध्य पूर्व पंक्तियाँ
- 2
स्रोत का अंश
EX-99.1 2 tm2530236d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results Quarterly Revenue Growth of 13% to ~$68 Million Gross Margin Increased to 43% on Improved Execution and Operational Efficiency Best-in-Class Clinical Profile for Lifileucel in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) with Median Duration of Response Not Reached after 25+ Months Follow Up SAN CARLOS, Calif., November 6, 2025 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported third quarter and year-to-date 2025 fi
इस संपत्ति पर और
उल्लेखनीय
6 अग॰ 2026
11:05 am
IOVAIovanceआयोवांस: सॉफ्ट टिश्यू सार्कोमा में lifileucel के लिए FDA Fast Track दर्जा
उल्लेखनीय
24 फ़र॰ 2026
01:00 pm
IOVAIovanceIovance को 2L+ एडवांस्ड NSCLC में lifileucel के लिए FDA Fast Track प्राप्त हुआ